Meta-Analysis of Cannabigerol Effects on Breast Cancer Tissue Cells

Published: May 4, 2021

Abstract: Cannabigerol (CBG) is one of over 120 cannabinoids known that is produced by the Cannabis sativa plant and has become of recent therapeutic interest. Cannabinoids target primarily cannabinoid receptors 1 and 2 (CBR1/CBR2) and form ligand-receptor complexes that can activate many cell signal transduction pathways, explaining its wide range of beneficial effects across many conditions. Positive effects with the introduction of CBG have been shown in research for Huntington’s Disease, appetite-consumption levels, antibacterial efforts, and numerous other areas. The impact of breast cancer is seen highest in the female population, and is a condition still searching for the best therapeutic treatment. Cell death is commonly seen as an immune response to target tumor aggregates in breast cancer.

This study looked specifically into the effect of CBG on two types of breast cancer cells (E3 luminal and EWD8 basal). In order to determine if the CBG could affect the cells, primers were designed for genes that were hypothesized in previous research to respond to CBD. The results were measured by a PCR. To measure the effects of cell proliferation and cell death, a MTT and cell trace assays were performed which suggested decreased proliferation and increased cell death. Based on these results, it appears that CBG slows proliferation and potentially induces necroptosis in human
breast cancer cell lines.